{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T20:53:23Z","timestamp":1761512003318},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2005,1]]},"DOI":"10.1016\/j.ejca.2004.08.029","type":"journal-article","created":{"date-parts":[[2004,11,6]],"date-time":"2004-11-06T13:01:23Z","timestamp":1099746083000},"page":"81-92","source":"Crossref","is-referenced-by-count":56,"title":["Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer"],"prefix":"10.1016","volume":"41","author":[{"given":"A.","family":"Martoni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Marino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Sperandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Giaquinta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Di Fabio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Melotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Guaraldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Palomba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Preti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Petralia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Artioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Picece","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Farris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Mantovani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2004.08.029_bib1","first-page":"23s","article-title":"Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why?","volume":"20","author":"Bunn","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2004.08.029_bib2","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1200\/JCO.1994.12.2.360","article-title":"Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients","volume":"12","author":"Le Chevalier","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2004.08.029_bib3","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1200\/JCO.1998.16.7.2459","article-title":"Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group trial","volume":"16","author":"Wozniak","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2004.08.029_bib4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0169-5002(98)00065-8","article-title":"Multicenter randomized clinical trial on high-dose epirubicin plus cis-platin versus vinorelbine plus cis-platinum in advanced non-small cell lung cancer","volume":"22","author":"Martoni","year":"1998","journal-title":"Lung Cancer"},{"issue":"Suppl. 8","key":"10.1016\/j.ejca.2004.08.029_bib5","first-page":"24","article-title":"Phase I\/II study of gemcitabine and cisplatin in the treatment of advanced non-small-cell lung cancer: preliminary results","volume":"24","author":"Steward","year":"1997","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ejca.2004.08.029_bib6","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1200\/JCO.1997.15.2.744","article-title":"Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer","volume":"15","author":"Abratt","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2004.08.029_bib7","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1200\/JCO.1997.15.1.297","article-title":"Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study","volume":"15","author":"Crin\u00f2","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2004.08.029_bib8","first-page":"158","article-title":"A Hoosier Oncology Group phase II study of gemcitabine plus cisplatin in non-small-cell lung cancer","volume":"1","author":"Sandler","year":"1998","journal-title":"Cancer Ther"},{"issue":"Suppl. 8","key":"10.1016\/j.ejca.2004.08.029_bib9","first-page":"27","article-title":"Phase II trial of gemcitabine and weekly cisplatin for advanced non-small-cell lung cancer","volume":"24","author":"Shepherd","year":"1999","journal-title":"Sem Oncol"},{"key":"10.1016\/j.ejca.2004.08.029_bib10","first-page":"461a","article-title":"Gemcitabine plus cisplatin in advanced NSCLC: final phase II results","volume":"16","author":"Anton","year":"1997","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2004.08.029_bib11","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2004.08.029_bib12","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1136\/bmj.320.7243.1197","article-title":"How should cost data in pragmatic randomised trials be analysed? Education and debate","volume":"320","author":"Thompson","year":"2000","journal-title":"Br Med J"},{"key":"10.1016\/j.ejca.2004.08.029_bib13","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/oxfordjournals.annonc.a058687","article-title":"Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial","volume":"5","author":"Depierre","year":"1994","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2004.08.029_bib14","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1200\/JCO.2001.19.13.3210","article-title":"Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial","volume":"19","author":"Kelly","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2004.08.029_bib15","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1200\/JCO.2002.02.068","article-title":"Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer","volume":"20","author":"Scagliotti","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2004.08.029_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.2003.12.046","article-title":"Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group","volume":"21","author":"Fossella","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2004.08.029_bib17","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1038\/bjc.1997.586","article-title":"Cisplatin and vinorelbine followed by ifosfamide plus epirubicin vs the opposite sequence in advanced unresectable stage III and metastatic stage IV non-small-cell lung cancer: a prospective randomised study of the Southern Italy Oncology Group (GOIM)","volume":"76","author":"Colucci","year":"1997","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2004.08.029_bib18","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0169-5002(02)00076-4","article-title":"Vinorelbine plus cisplatin versus cisplatin plus vindesine and mitomycin C in stage IIIB-IV non-small-cell lung carcinoma: a prospective randomised study","volume":"37","author":"Gebbia","year":"2002","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejca.2004.08.029_bib19","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0169-5002(02)00444-0","volume":"39","author":"Gebbia","year":"2003","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejca.2004.08.029_bib20","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00280-003-0707-8","article-title":"Phase II study of the combination of vinorelbine and cisplatin in advanced non-small-cell lung cancer","volume":"53","author":"Mori","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2004.08.029_bib21","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1200\/JCO.2000.18.1.122","article-title":"Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer","volume":"18","author":"Sandler","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2004.08.029_bib22","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejca.2004.08.029_bib23","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1200\/JCO.1999.17.11.3522","article-title":"Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project","volume":"17","author":"Crin\u00f2","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2004.08.029_bib24","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1200\/JCO.1999.17.1.12","article-title":"Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer","volume":"17","author":"Cardenal","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2004.08.029_bib25","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1200\/JCO.2003.12.038","article-title":"Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial","volume":"21","author":"Alberola","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2004.08.029_bib26","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1200\/JCO.2003.03.195","article-title":"Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group\u2013EORTC 08975","volume":"21","author":"Smit","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2004.08.029_bib27","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1200\/JCO.1986.4.12.1780","article-title":"A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma","volume":"4","author":"Klastersky","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2004.08.029_bib28","first-page":"782","article-title":"Cisplatin and vindesine combination chemotherapy for non-small lung cancer: a randomized trial comparing two dosages of cisplatin","volume":"77","author":"Shinkai","year":"1986","journal-title":"Jpn J Cancer Res"},{"key":"10.1016\/j.ejca.2004.08.029_bib29","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1200\/JCO.2003.06.099","volume":"21","author":"Gridelli","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2004.08.029_bib30","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/jnci\/95.5.362","article-title":"Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial","volume":"95","author":"Gridelli","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2004.08.029_bib31","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/jnci\/94.4.291","article-title":"Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer","volume":"94","author":"Ramsey","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2004.08.029_bib32","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1200\/JCO.2001.19.5.1336","article-title":"Duration of chemotherapy in advanced non-small cell lung cancer: a randomised trial of three versus six courses of mitomycin, vinblastine, and cisplatin","volume":"19","author":"Smith","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2004.08.029_bib33","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1200\/JCO.20.5.1335","article-title":"Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced stage IIIB\/IV non-small-cell lung cancer","volume":"20","author":"Socinski","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2004.08.029_bib34","first-page":"309a","article-title":"Maintenance chemotherapy in advanced non-small-cell lung cancer (NSCLC): a randomized study of vinorelbine (V) versus observation (OB) in patients (Pts) responding to induction chemotherapy (French Cooperative Oncology Group)","volume":"20","author":"DePierre","year":"2001","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804904007725?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804904007725?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,2]],"date-time":"2019-02-02T04:20:09Z","timestamp":1549081209000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804904007725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["S0959804904007725"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2004.08.029","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2005,1]]}}}